A 17% Reduction in Overall Cancer Risk A landmark study published in JAMA Oncology (Dai H et al., August 2025), drawing on data from 14 health systems encompassing approximately 20 million patients, found that adults with obesity who were prescribed GLP-1 receptor agonists had a 17% lower risk of developing cancer compared to carefully matched non-users
Loa apsorpcija Bez pojaivaa bioraspoloivosti, ak i dobro formulirani dodaci mogu proi kroz crijeva prije nego to se aktivne tvari u potpunosti apsorbiraju, ime se njihov stvarni uinak znaajno smanjuje
The country turns 250 on Saturday, and we're kicking off the Fourth of July weekend with a celebration and a special russian message to America
This triple-action mechanism distinguishes it from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
None of these drugs work as well as semaglutide or tirzepatide, experts say, but they may help with weight loss maintenance
/assets/images/provider/photos/2665301.jpg)
